The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance
Open accessAbstract
Somatostatin receptors expressed on tumor cells form the rationale for somatostatin analog treatment of patients with somatostatin receptor-positive neuroendocrine tumors.Nevertheless, although somatostatin analogs effectively control hormonal hypersecretion by GH-secreting pituitary adenomas, islet cell tumors, and carcinoid tumors, significant differences are observed among patients with respect to the efficacy of treatment.This may be related to a differential expression of somatostatin receptor subtypes among tumors.In addition, the property of somatostatin receptor subtypes to undergo agonist-induced internalization has important con-sequences for visualizing, as well as for therapy, of receptorpostive tumors using radioisotope-or chemotherapeuticcompound-coupled somatostatin analogs.This review covers the pathophysiological role of somatostatin receptor subtypes in determining the efficacy of treatment of patients with somatostatin receptor-positive tumors using somatostatin analogs, as well as the preclinical and clinical consequences of agonist-induced receptor internalization for somatostatin receptor-targeted radio-and chemotherapy.Herein, the development and potential role of novel somatostatin analogs is discussed.(Endocrine Reviews 24: 28 -47, 2003) I. General Introduction A. SS and sst subtypes B. SS receptor subtype expression in normal and tumorous human tissues C. Agonist-induced internalization of sst subtypes II.Consequences of sst Internalization for sst-Targeted Radiotherapy or Chemotherapy of sst-Positive Tumors A. Preclinical evidence for internalization of radiolabeled SS-analogs B. SS receptor-targeted radiotherapy C. SS receptor-targeted chemotherapy: preclinical evidence III.Tachyphylaxis and Resistance to SS A. Introduction B. Tachyphylaxis of pathological hormone secretion C. Escape from antiproliferative effects D. Mechanisms of tachyphylaxis and resistance E. New developments F. Conclusions IV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Somatostatin and Its Receptor Family
Patel, Y. C. (1999) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0183 · Cited by 1,648
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Self-citationEndocytosis and the recycling of plasma membrane.
Steinman, R. M., Mellman, I. S., Muller, W. A., & Cohn, Z. A. (1983) · The Journal of cell biology · doi:10.1083/jcb.96.1.1 · Cited by 1,450
Turning off the signal: desensitization of β‐adrenergic receptor function
Hausdorff, W. P., Caron, M. G., & Lefkowitz, R. J. (1990) · The FASEB Journal · doi:10.1096/fasebj.4.11.2165947 · Cited by 1,249
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
THE ROLE OF RECEPTOR KINASES AND ARRESTINS IN G PROTEIN–COUPLED RECEPTOR REGULATION
Krupnick, J. G., & Benovic, J. L. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.289 · Cited by 1,103
Reichlin, S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312153092406 · Cited by 1,044
Two G Protein Oncogenes in Human Endocrine Tumors
Lyons, J., Landis, C. A., Harsh, G., Vallar, L., Grünewald, K., Feichtinger, H., Duh, Q.-Y., Clark, O. H., Kawasaki, E., Bourne, H. R., et al. (1990) · Science · doi:10.1126/science.2116665 · Cited by 1,037
Lamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., & Hofland, L. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340408 · Cited by 1,001
Self-citation
Cited by
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
A 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
Opportunities in somatostatin research: biological, chemical and therapeutic aspects
Weckbecker, G., Lewis, I., Albert, R., Schmid, H. A., Hoyer, D., & Bruns, C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1255 · Cited by 559
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 515
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
MODLIN, I. M., PAVEL, M., KIDD, M., & GUSTAFSSON, B. I. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04174.x · Cited by 410
Regulation and function of somatostatin receptors
Olias, G., Viollet, C., Kusserow, H., Epelbaum, J., & Meyerhof, W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02402.x · Cited by 318
Rationale for the use of somatostatin analogs as antitumor agents
Susini, C., & Buscail, L. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl105 · Cited by 304
Pasireotide (SOM230): Development, mechanism of action and potential applications
Schmid, H. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.09.006 · Cited by 290
Resistance to Somatostatin Analogs in Acromegaly
Colao, A., Auriemma, R. S., Lombardi, G., & Pivonello, R. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0002 · Cited by 257
Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H.-J., Lupp, A., Korbonits, M., Castaño, J. P., Wester, H.-J., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 253
Carcinoid syndrome: diagnosis and medical management
van der Lely, A. J., & Herder, W. W. D. (2005) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302005000500028 · Cited by 73
Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors
Pivonello, R., Ferone, D., de Herder, W. W., Faggiano, A., Bodei, L., de Krijger, R. R., Lombardi, G., Colao, A., Lamberts, S. W. J., & Hofland, L. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0728 · Cited by 68
Self-citationTherapeutic strategies for patients with neuroendocrine neoplasms: current perspectives
Modica, R., Liccardi, A., Minotta, R., Cannavale, G., Benevento, E., & Colao, A. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099840 · Cited by 37
Metadata
- Authors
- Hofland, L. J., & Lamberts, S. W. J.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2003-02-01
- Volume
- 24
- Issue
- 1
- Pages
- 28-47
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2140741951
- Cited by
- 474
- References
- 116
- FWCI
- 19.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.